Role of thermodynamic and kinetic parameters in gadolinium chelate stability

Journal of Magnetic Resonance Imaging

Volumn 30, Issue 6, 2009, Pages 1249-1258

  Idée, Jean Marc ^a   Port, Marc ^a   Robic, Caroline ^a   Medina, Christelle ^a   Sabatou, Monique ^a   Corot, Claire ^a  

^a Laboratoire Guerbet   (France)

Author keywords

Gadolinium chelates; Kinetic stability; Thermodynamic stability; Transmetallation

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM CHLORIDE; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; MEGLUMINE;

CHELATION; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DISSOCIATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HYDROPHILICITY; ION TRANSPORT; LIPOPHILICITY; METALLATION; NONHUMAN; OSMOLALITY; PRIORITY JOURNAL; SINGLE DRUG DOSE; THERMOSTABILITY; VISCOSITY;

ANIMALS; CHELATING AGENTS; CONTRAST MEDIA; DRUG STABILITY; GADOLINIUM; HUMANS; KIDNEY; KINETICS; MAGNETIC RESONANCE IMAGING; METABOLIC CLEARANCE RATE; NEPHROGENIC FIBROSING DERMOPATHY; ORGAN SPECIFICITY; THERMODYNAMICS; TISSUE DISTRIBUTION;

EID: 73649093454     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21967     Document Type: Conference Paper

References (71)

1. De Haën C. Conception of the first magnetic resonance imaging contrast agents: a brief history. Top Magn Reson Imaging 2001;12:221-230.
2. Guerbet annual report (2007) http//www.guerbet.com/fileadmin/user-upload/ investors/reports/2007/lang-en/annual-report-2007.pdf Accessed 10 October, 2008.
3. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999;99:2293-2352.
4. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?Nephrol Dial Transplant 2006;21:1104-1108.
5. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362.
6. Tweedle MF, Hagan JJ, Kumar K, et al. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging 1991;9:409-415
7. Idée JM, Berthommier C, Goulas V, et al. Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation. Biometals 1998;11:113-123.
8. Gibby WA, Gibby KA, Gibby WA. Comparison of Gd-DTPA-BMA (Omniscan) versus Gd-HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 2004;39:138-142.
9. Kuo PH. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. J Am Coll Radiol 2008;5:29-35.
10. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008;66:175-179.
11. Idée JM, Port M, Medina C, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88.
12. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium-based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007;80:73-76.
13. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Safety 2008;3:67-75.
14. Mellor DP. Historical background and fundamental concepts. In: Dwyers FP, Mellor DP, editors. Chelating agents and metal chelates. New York: Academic Press; 1964. p 1-50.
15. Brücher E, Sherry AD. Stability and toxicity of contrast agents. In: Merbach AE, Toth E, editors. The chemistry of contrast agents in medical magnetic resonance imaging. Chichester, UK: John Wiley & Sons; 2001. p 243-279.
16. Wastie ML, Latief KH. Gadolinium: named after Finland's most famous chemist. Br J Radiol 2004;77:146-147.
17. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 1987;87:901-927.
18. Williams DR, Halstead BW. Chelating agents in medicine. J Toxicol Clin Toxicol 1982;19:1081-1115.
19. Palasz A, Czekaj P. Toxicological and cytophysiological aspects of lanthanides action. Acta Biochim Pol 2000;47:1107-1114.
20. Quarles LD, Hartle JE 2nd, Middleton JP, et al. Aluminium-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism. J Cell Biochem 1994;56:106-117.
21. Spencer AJ, Wilson SA, Batchelor J, et al. Gadolinium chloride toxicity in the rat. Toxicol Pathol 1997;25:245-255.
22. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009;44:74-81.
23. Idée JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-576.
24. Port M, Idée JM, Medina C, et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences. Biometals 2008;21:469-490.
25. VanWagoner M, O'Toole M, Worah D, et al. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol 1991;26:980-986.
26. Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007;26:1190-1197.
27. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195:785-792.
28. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999;6:282-291.
29. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
30. Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 1999;34:443-448.
31. Tombach B, Bremer C, Reimer P, et al. Pharmacokinetics of 1 M gadobutrol in patients with chronic renal failure. Invest Radiol 2000;35:35-40.
32. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol 2007;80:581-585.
33. 3+ with 1,4,7,10-tetrakis (carboxymethyl)-1,4,7,10-tetraazacyclododecane (dota). Characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence spectroscopy, and EXAFS. Chem Eur J 2004;10:5218-5232.
34. Döhr O, Hofmeister R, Treher M, et al. Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Invest Radiol 2007;42:830-841.
35. Laurent S, Vander Elst L, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Med Mol Imaging 2006;1:128-137.
36. Steger-Hartmann T, Graham PB, Muller S, et al. Preclinical safety assessment of Vasovist (gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography. Invest Radiol 2006;41:449-459.
37. Uggeri F, Aime S, Anelli PL, et al. Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln = Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8, 11-triazatridecan-13-oato(5-)] gadolinite(2-) in a mixture with its enantiomer. Inorg Chem 1995;34:633-642.
38. 2+ complexes of macrocyclic polyamino carboxylates. Inorg Chem 1995;34:6472-6480.
39. Desreux JF, Barthélémy PP. Highly stable lanthanide macrocyclic complexes: in search of new contrast agents for NMR imaging. Nucl Med Biol 1988;1:9-15.
40. Tóth E, Brücher E, Lazar I, et al. Kinetics of formation and dissociation of lanthanide(III)-DOTA complexes. Inorg Chem 1994;33:4070-4076.
41. Tóth E, Kiraly R, Platzek J, et al. Equilibrium and kinetic studies on complexes of 10-[2,3-dihydroxy-(1-hydroxymethyl)-propyl]-1,4,7,10- tetraazacyclododecane-1,4,7-triacetate. Inorg Acta 1996;249:191-199.
42. Brücher E. Kinetic stability of gadolinium (III) chelates used as MRI contrast agents. In: Topics in current chemistry, 221. Berlin: Springer; 2002. p 103-122.
43. Evans CH. The occurrence and metabolism of lanthanides. In: Evans CH, editor. Biochemistry of the lanthanides. New York: Plenum Press; 1990. p 285-337.
44. Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2007;2:199-205.
45. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008;158:273-280.
46. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-26.
47. Tweedle MF. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992;27(suppl 1):S2-S6.
48. Kumar K, Chang CA, Tweedle MF. Equilibrium and kinetic studies of lanthanide complexes of macrocyclic polyamino carboxylates. Inorg Chem 1993;32:587-593.
49. Pulukkody KP, Norman TJ, Parker D, et al. Synthesis of charged and uncharged complexes of gadolinium and yttrium with cyclic polyazaphosphinic acid ligands for in vivo applications. J Chem Soc Perkin Trans 1993;2:605-620.
50. Laurent S, Vander Elst L, Copoix F, et al. Stability of MRI paramagnetic contrast media. A proton relaxometric protocol for transmetallation assessment. Invest Radiol 2001;36:115-122.
51. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based contrast agents in human serum at 37°C. Invest Radiol 2008;43:817-828.
52. Lin J, Idée JM, Port M, et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. J Pharm Biomed Anal 1999;21:931-943.
53. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology 2003;227:639-646.
54. Kumar K. Macrocyclic polyamino carboxylate complexes of Gd (III) as magnetic resonance imaging contrast agents. J Alloys Comp 1997;249:163-172.
55. Caravan P, Comuzzi C, Crooks W, et al. Thermodynamic stability and kinetic inertness of MS325, a new blood pool agent for magnetic resonance imaging. Inorg Chem 2001;40:2170-2176.
56. Meyer D, Schaefer M, Bonnemain B. Gd-DOTA, a potential MRI contrast agent. Current status of physicochemical knowledge. Invest Radiol 1988;23(suppl 1):S232-S235.
57. Wang X, Jin T, Comblin V, et al. A kinetic investigation of the lanthanide DOTA chelates. Stability and rates of formation and of dissociation of a macrocyclic gadolinium (III) polyaza polycarboxylic MRI contrast agent. Inorg Chem 1992;31:1095-1099.
58. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990;8:467-481.
59. 3+ complex employed as paramagnetic contrast agent in NMR imaging. Inorg Chim Acta 1999;288:244-248.
60. 2-, used as a contrast agent in magnetic resonance imaging. Chem Eur J 2000;6:719-724.
61. Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol 1996;31:739-742.
62. + ions. Contrast Med Mol Imaging 2006;1:23-29.
63. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995;30:372-380.
64. Harrison A, Walker CA, Pereira KA, et al. Hepato-biliary and renal excretion in mice of charged and neutral gadolinium complexes of cyclic tetra-aza-phosphinic and carboxylic acids. Magn Reson Imaging 1993;11:761-770.
65. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008;43:65-75.
66. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agent. Invest Radiol 2009;44:226-233.
67. Grant D, Johnsen H, Juelsrud A, et al. Effects of gadolinium contrast agents in naïve and neprectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol 2009;50:156-169.
68. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled mass spectroscopy. Invest Radiol 2006;41:272-278.
69. Edginton AN, Theil FP, Schmitt W, et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008;4:1143-1152.
70. Hirano S, Suzuki KT. Exposure, metabolism, and toxicity of rare earths and related compounds. Environ Health Perspect 1996;104(suppl 1):85-95.
71. Behets GJ, Verberckmoes SC, Oste L, et al. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005;67:1830-1836.